Skip to main content

Advertisement

Table 1 Subjects’ baseline characteristics

From: Reduction of delayed onset muscle soreness by a novel curcumin delivery system (Meriva®): a randomised, placebo-controlled trial

  Placebo (n = 10) Mean ± SD 95% CI Curcumin (n = 9) Mean ± SD 95% CI
Age (years) 38.1 ± 11.1 30.1;46.1 32.7 ± 12.3 23.1;42.1
Height (cm) 174.8 ± 3.0 172.7;176.9 176.6 ± 3.6 173.7;179.4
Weight (kg) 75.8 ± 6.5 71.2;80.4 76.2 ± 4.2 73.0;79.5
BMI (kg/m2) 24.8 ± 1.7 23.6;26.0 24.4 ± 1.0 23.6;25.2
VO2/kg (ml/kg) 45.8 ± 4.7 42.5;49.2 48.9 ± 5.3 44.8;53.1
Maximal speed (maximal exercise test) (km/h) 13.7 ± 1.8 12.4;15.0 14.8 ± 1.1 13.9:15.6
Speed at the anaerobic threshold (km/h) 10.9 ± 1.7 6.6;12.1 11.8 ± 1.5 10.6;12.9
Speed during the injury provocation test (km/h) 10.9 ± 1.2 10.0;11.7 11.4 ± 0.9 10.8;11.4